Novo Nordisk (NYSE: NVO) stock tumbled 8.1% through 11:35 a.m. ET Monday, and it has only itself to blame. Novo, you see, just told investors what to expect from its stock over the next five years -- and even the next 10 years! -- and investors aren't liking what they heard one bit. Missed AI's "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »Image source: Getty Images. Novo in 2026-2030 -- and 2035, too Between now and 2030, Novo Nordisk plans to launch more than five separate "multi-blockbuster" new drugs.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.